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Abstract
Background: Rural areas of India exhibit high neonatal mortality, and low literacy and numeracy. We assess the
effect of a complex package of health interventions on neonatal survival and the effect of out-of-school-hours
teaching on children’s literacy and numeracy in rural Madhya Pradesh.
Methods/design: This is a cluster-randomised controlled trial with villages (clusters) receiving either a health
(CHAMPION2) or education (STRIPES2) intervention. Building on the design of the earlier CHAMPION/STRIPES trial,
villages receiving the health intervention are controls for the education intervention and vice versa.
The clusters are 196 villages in Satna district, Madhya Pradesh, India: each is at least 5 km from a Community Health
Centre, has a population below 2500, and has at least 15 children eligible for the education intervention. The
participants in CHAMPION2 are resident married women younger than 50 years of age who had not undergone a
family planning operation, provided they are enumerated pre-randomisation or marry a man enumerated pre-
randomisation. The participants in STRIPES2 are resident children born 16 June 2010 to 15 June 2013, not in school
before the 2018–2019 school year and intending to enrol in first grade in 2018–2019 or 2019–2020.
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Discussion: In CHAMPION2, the NICE Foundation will deliver a 3.5-year programme comprising Accredited Social
Health Activists or village health workers and midwives promoting health knowledge and providing antenatal,
postnatal, and neonatal healthcare; community mobilisation; referrals to appropriate government health facilities; and a
health education campaign. In STRIPES2, the Pratham Education Foundation will deliver a programme of village-based,
before/after school support focusing on literacy and numeracy. As controls, the CHAMPION2 control villages will
receive the usual health services (plus the STRIPES2 intervention). STRIPES2 control villages will receive the usual
education services (plus the CHAMPION2 intervention). The primary outcome in CHAMPION2 is neonatal mortality.
Secondary outcomes include antenatal, delivery, immediate neonatal and postnatal care practices, maternal mortality,
stillbirths, early neonatal deaths, perinatal deaths, health knowledge, hospital admissions, maternal blood transfusions,
and cost effectiveness. The primary outcome in STRIPES2 is a composite literacy and numeracy test score. Secondary
outcomes include separate literacy and numeracy scores, reported school enrolment and attendance, parents’
engagement with children’s learning, and cost effectiveness. Independent research and implementation teams will
conduct the trial. Trial Steering and Data Monitoring Committees, with independent members, will supervise the trial.
Trial registration: Clinical Trial Registry of India: CTRI/2019/05/019296. Registered on 23 May 2019. http://www.ctri.nic.
in/Clinicaltrials/pdf_generate.php?trialid=31198&EncHid=&modid=&compid=%27,%2731198det%27
Keywords: Cluster randomised controlled trial, India, Neonatal mortality, Immediate neonatal care, Postnatal care,
Maternal mortality, Stillbirths, Primary education, Supplementary teaching, Literacy, Numeracy
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Introduction
Background and rationale {6a}
CHAMPION2
It is estimated that 2.6 million neonatal deaths occur
annually, of which 24% (640,000) are in India [1]. In 2015,
the major determinants of neonatal deaths in India were
prematurity and low birth weight (44%), birth asphyxia
and birth trauma (19%), and neonatal infections (19%) [2].
Despite India’s rapid economic growth, there has been
little progress in improving neonatal survival [2].
According to the Sample Registration System Statistical
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Report 2017, India’s neonatal mortality rate (NMR) is 23
per 1000 live births [3]. Estimates vary widely between the
different states i.e. the NMR is 5 per 1000 live births in
Kerala and 33 per 1000 live births in Madhya Pradesh [3].
There are large disparities in health, with NMRs almost
twice higher in rural areas compared to urban areas (14
and 27 per 1000 live births in urban and rural areas,
respectively) [3]. The state of Madhya Pradesh is
characterised by a marginalised, tribal population, where
less than 30% of mothers in rural villages have four or
more antenatal care visits and the proportion of illiterate
women is about 50% [4]. Within the state, the NMR
ranges between 24 per 1000 live births in Indore district,
and 57 per 1000 live births in Satna district [5].
India, like other South Asian countries, has national
programmes aimed at improving maternal and neonatal
health. In 2005, India’s National Rural Health Mission
(NRHM), now a component of the National Health
Mission, launched Janani Suraksha Yojana (JSY), a
major safe motherhood intervention to reduce maternal
and neonatal mortality by promoting institutional
deliveries [6]. JSY is a conditional cash transfer
scheme targeting poor pregnant women who deliver
in health facilities and receive postnatal care [6].
The JSY is responsible for increasing the proportion of
deliveries occurring in health facilities from 26% in 2005
to 81% in 2015 in Madhya Pradesh [4, 6]. Despite this
initiative, there has not been a corresponding reduction
in neonatal mortality in Madhya Pradesh [7]. There is
also evidence suggesting that the quality of care in some
facilities is substandard [7, 8].
Another key element of the NRHM is the Accredited
Social Health Activist (ASHA). The ASHA acts as an
effective link between the government and community by
facilitating pregnant women in accessing antenatal care,
delivery in a health facility, postnatal care, and other
available health services. The ASHA receives performance-
based incentives for her various services, which include re-
ferral and escort services for pregnant women under
NRHM [6, 9]. ASHAs have also been trained to provide
home-based neonatal care through postnatal home visits
and providing health education through community mobil-
isation [9]. Evaluations have shown that the NRHM has had
a positive impact on increasing attendance at antenatal care
and institutional deliveries, and on immunisation rates [8].
Scaling up community programmes worldwide to
improve neonatal health has the potential to reduce
neonatal mortality by 24% [10]. Community support,
community mobilisation, home visits by trained community
health workers, and strengthening referral systems are the
most effective community-based interventions [10].
Evidence-based research has also prompted the World
Health Organisation (WHO) and UNICEF’s Every Newborn
Action Plan to recommend these approaches [11].
Over the past 15 years, there have been several trials
aiming to improve maternal and neonatal health
through home visits; some of these trials took place in
India [12–14]. A study in Uttar Pradesh, India, found
that an intervention that included home visits and
community meetings led to improved care practices and
neonatal survival [13]. Another study evaluated the
effectiveness of scaling up India’s Integrated
Management of Neonatal and Childhood Illness
(IMNCI) strategy that included postnatal home visits
and treating sick neonates in accordance to pre-defined
guidelines. Findings suggested that the IMNCI strategy
has the potential to reduce neonatal mortality by 12%
when brought to scale [14].
Community mobilisation is the other main approach
to community health, in particular, community
mobilisation through participatory learning and action
(PLA) [15]. PLA includes women’s groups operated by
women identifying problems relevant to their own
health needs, coming up with culturally acceptable
solutions, and implementing these solutions [15]. A
meta-analysis and systematic review testing the impact
of community mobilisation using PLA with women’s
groups, which also included five studies from South
Asia, suggested this to be a highly effective and low-cost
intervention in reducing neonatal and maternal mortality
[15]. A recent cluster randomised controlled trial (cRCT)
demonstrated that ASHAs can reduce neonatal mortality
using the PLA approach with women’s groups [16]. The
Indian government has now mandated ASHAs to deliver
PLA through women’s groups in 18 separate states in
India, beginning with Odisha and Jharkhand [17].
The original CHAMPION trial randomised 464
villages in Telangana, India. Villages were randomised to
an intervention aimed at reducing neonatal mortality or
to a control arm offering the usual ongoing health
services. The health intervention included a package
comprising community health promotion (i.e. health
education through village health worker-led participa-
tory discussion groups), outreach (i.e. mobile teams pro-
viding antenatal and postnatal care in the home or
through fixed day health services), and provision of
facility-based care (i.e. subsidised access to non-public
health centres) [18]. The primary outcome of neonatal
mortality was significantly lower in the intervention arm
compared to the control arm (52 neonatal deaths per
1000 live births versus 69 deaths per 1000 live births), a
reduction of 24% (relative risk 0.76; 95% CI 0.64 to 0.90;
p = 0.0018). The authors concluded that the CHAM-
PION intervention was strongly justified in this setting,
but the trial needed adaptation and further development
for evaluation in other areas [18].
The objective of the CHAMPION2 trial is to assess
whether an adapted intervention is also able to improve
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neonatal survival, albeit in a different region of India.
The original study design will be further developed
using lessons learned from the original CHAMPION
trial, as well as relevant evidence generated since the
conception of the original trial. The CHAMPION2 trial
will also be contextualised to socio-cultural patterns and
behaviours relating to neonatal and maternal health in
Madhya Pradesh, India.
STRIPES2
India has made steady progress in improving rates of
primary school enrolment. In rural areas, about 97% of
children between 6 and 14 years of age are now in
school [19]. The levels of learning achievement,
however, remain low. The 2018 Annual Status of
Education Report (ASER) survey shows that proficiency
in reading and numeracy is worryingly low and Indian
children may spend several years in school without
learning even the basic skills in literacy and numeracy
[19].
Several strategies have been proposed to address the
low quality of education, but many of these approaches
fail to improve children’s learning as they tend to
exclusively address the provision of facilities, materials
and access to school rather than improve the child’s
experience in the learning process [20–25].
Few studies have systematically measured the impact
of supplementary teaching on learning outcomes.
Evidence from Chile and India shows that providing
extra teaching with tutors hired from the local
community successfully raises the scores of low-
performing children [26–28]. A 3-month tutoring
programme targeting fourth grade, low-performing stu-
dents in Chile significantly increased pupils’ reading
skills [28]. In India, a programme that provided remedial
classes for third and fourth grade pupils in public
schools of Mumbai and Vadodara increased the overall
test scores in literacy and numeracy by 0.28 SD in the
second year of the programme [26]. Another study in
Uttar Pradesh, India showed a positive impact on read-
ing skills in children who had a high attendance in read-
ing camps led by community volunteers [25].
In Telangana, the STRIPES trial intervention, which
included children attending public primary schools,
demonstrated important results in improving numeracy
and language scores [27]. This trial evaluated the
effectiveness of an intervention that provided 18months
supplementary, remedial teaching and learning materials
(and an additional “kit” of materials for girls). The primary
outcome was a composite of language and numeracy test
scores. These scores were significantly higher in the
intervention group (107 villages; 2364 children) than in the
control group (106 villages; 2014 children) at the end of the
trial (mean difference on a percentage scale 15.8; 95% CI
13.1 to 18.6; p = 0.001; 0.75 Standard Deviation (SD)
difference). Composite test scores were not significantly
different in the 54 villages (614 girls) with the additional
kits for girls compared to the 53 villages (636 girls) without
these kits at the end of the trial (mean difference on a
percentage scale 0.5; 95% CI − 4.34 to 5.4; p = 0.84). The
STRIPES trial provided strong evidence that supplementary
teaching implemented in remote rural areas has a strong
impact in improving numeracy and literacy skills. Given the
little evidence found in previous trials, it would be
beneficial to adapt and further develop the STRIPES trial to
determine whether the study findings are generalizable to
different settings.
Taking into consideration the above evidence, the
primary aim of STRIPES2 is to assess whether an
intervention adapted from Pratham’s current model of
working with early grades has a similar effect on the
literacy and numeracy of primary school age children in
Madhya Pradesh, using a design developed from the
STRIPES trial.
Objectives {7}
Our main research question is whether the success of
the CHAMPION and STRIPES trial interventions can be
further generalised, after appropriate adaptations and
developments, in Madhya Pradesh. This new cluster-
randomised trial therefore combines the further devel-
oped versions of the previous CHAMPION (addressing
neonatal survival) and STRIPES (addressing learning
levels among primary-school-age children) interventions.
Participants in the control arm of the health intervention
will receive the education intervention, whereas partici-
pants in the control arm of the education intervention
will receive the health intervention.
This protocol has been written taking into account the
Standard Protocol Items: Recommendation for
Interventional Trials (SPIRIT) guidelines [29].
Trial design {8}
This study is a cluster-randomised controlled trial with
villages receiving either a health (CHAMPION2) or edu-
cation (STRIPES2) intervention.
Methods: participants, interventions and
outcomes
Study setting {9}
The trial will take place in Satna district, Madhya
Pradesh, with a population of 2.23 million, of which 79%
live in a rural setting with a predominantly agrarian
economy [30, 31]. In terms of education, between 2006
and 2018, Madhya Pradesh has experienced an increase
in school enrolment rates [19]. In rural villages, 96% of
children between 6 and 14 years old, and 94% between
11 and 14 years old were enrolled in school in 2018 [19].
Agarwal et al. Trials          (2020) 21:569 Page 4 of 18
However, the achievement in basic reading was very low
with only about 18% of children in grade 3 being able to
read a short story (7–10 sentences) in the local language
[19].
In terms of neonatal health, Satna has one of the
highest NMRs in Madhya Pradesh, with a higher NMR
in rural compared to urban areas (61 per 1000 live
births in rural areas, and 43 per 1000 live births in urban
areas) [5]. Satna is also the second worst performing
district in terms of neonatal, infant, and child mortality
in Madhya Pradesh [4], which is the state with the
highest NMR in India [3].
The Government delivers health care through Sub-
Centres, Primary Health Centres (PHCs), Community
Health Centres (CHCs) and Civil Hospitals (CHs), and
one District Hospital (DH), which has a Special New-
born Care Unit (SNCU).
In Satna district, only 23.1% of the pregnant women
had four or more antenatal care visits, 85.8% received
tetanus toxoid vaccination, 17.1% consumed iron folic
acid (IFA) for 100 days or more, and 7.6% received full
antenatal care (i.e. at least four or more antenatal care
visits, at least one tetanus toxoid injection, and IFA for
100 days or more) [4]. Overall, 80% of deliveries in the
district occur in health facilities [4]. Approximately
56.2% of mothers received a postnatal check-up within
48 h of delivery [4]. Satna district has an ambulance sys-
tem (the 108 and Janani Surakhsa Express (JE)), respon-
sible for transporting pregnant women and babies with
serious health complications to the district hospital [32].
Whereas JE was considered relatively accessible to even
the most marginalised populations, anecdotal evidence
suggests that in practice there may be long delays, espe-
cially in areas that are difficult to access [32, 33]. Re-
cently these two systems have been merged, and a single
transport system (108) addresses all kinds of medical
needs, not just pregnancy and neonatal needs. Hence,
transport may not always be speedily available.
Emergency obstetric care (EmOC) is a package of
medical interventions required to treat seven obstetric
complications [34, 35]. The medical interventions
included in this package comprise parenteral antibiotics,
oxytocic drugs and anticonvulsants, manual removal of
placenta, removal of retained products, and assisted
vaginal deliveries [35]. Evidence suggests that birth
attendants in JSY facilities in Madhya Pradesh are often
not able to perform EmOC adequately [6, 36]. These
findings may help to explain why there has not been a
corresponding improvement in neonatal survival despite
increased rates of facility-based deliveries.
Eligibility criteria {10}
The trial will be conducted in Satna district, Madhya
Pradesh, India. Satna district is further divided into 10
tehsils (sub-districts). Three tehsils (Birsinghpur,
Majhgawan, and Raghurajnagar) were excluded due to
difficult access (forest area), risk of violent robbery, and
being an urban sub-district. The remaining seven tehsils
potentially eligible for the trial comprise 1263 villages
(68% of all villages in Satna), with a population of 1,441,
930 [30].
In these seven tehsils, villages were included if they:
1. Were considered rural, with fewer than 2500
population and with more than 120 children under
the age of 6 years [30] (villages where we did not
find at least 15 children eligible for STRIPES2 were
excluded after enumeration);
2. Were accessible by road;
3. Were not within a 5 km radius of the Community
Health Centres (as such villages are already well-
served by the local health services);
4. Had a minimum of 3 km between the centres of the
villages (to avoid “contamination”, though even with
that buffer we may have some contamination as
villages are very spread out).
From July 2017 to January 2018, we conducted a
baseline enumeration to enlist the eligible women and
children.
A woman was eligible for CHAMPION2 if during
enumeration she satisfied all the following criteria:
1. She was married
2. Neither she nor her husband had a family planning
operation (i.e. tubectomy or vasectomy)
3. She was younger than 50 years of age
4. She was resident of one of the trial villages at the
time of the baseline survey
5. She gave her consent after being given a complete
explanation of the study
In addition, a woman was considered eligible if she
married a man who was enumerated and unmarried at
the time of enumeration, resident of the village, and
aged between 13 and 50 years. If an eligible woman died,
her widowed husband was added to the list of
unmarried men. If this widowed man married again then
his wife was considered eligible.
The woman had to fulfil the usual criteria for
eligibility including being younger than 50 years of age,
resident of the village, gave her consent, and neither she
nor her husband have had a family planning operation.
Women (and their babies) who moved to a trial village
for other reasons (e.g. their mother’s residence for
delivery of their baby) were not included in the study,
and will not have access to the antenatal and postnatal
care provided by the intervention team (unless they were
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enumerated in another CHAMPION2 intervention
village).
For the primary trial analysis, we will start counting
births and deaths 12 months after the randomisation.
This lag in measurement is necessary to ensure adequate
exposure to the intervention taking into account both
the time interval between conception and birth, and the
fact that training and establishment of services in
intervention villages will take around 6 months.
A child was considered eligible for STRIPES2 if:
1. She/he was born between 16 June 2010 and 15 June
20131
2. She/he was not yet enrolled in primary school
3. She/he was expected to be resident in the village
and be enrolled in school for the first time, in the
first grade in the academic year of 2018–2019
4. Her/his parents agreed that she/he participates after
hearing the explanation about the programme and
its evaluation tests
For STRIPES2, only children who are enumerated at
baseline and present for the test will be considered in
the final analysis. Children who move into the trial
villages will not be included after enumeration.
Women and the parents of the children enumerated
were informed that they may withdraw from the trial at
any time.
Catch-up enumeration: before randomisation of villages,
from April–June 2019 we conducted a catch-up enumer-
ation in all the selected villages to enlist the eligible
women and children who were missed during baseline
enumeration, and updated the marital status of any previ-
ously enlisted unmarried men. If a man who was unmar-
ried during baseline enumeration was discovered to have
since married, then his name was removed from the un-
married men list and his wife was considered as eligible.
A child was considered eligible for STRIPES2 at the
catch-up enumeration if:
1. She/he was born between 16 June 2010 and 15 June
20133
2. She/he was enrolled in grade 1 in primary school in
the 2018–19 school year or was planning to enter
grade 1 in 2019–20
3. She/he was expected to be resident in the village in
2019–2020
4. Her/his parents agreed that she/he participates after
hearing the explanation about the programme and
its evaluation tests
Knowledge, attitudes, and practices (KAP) survey:
before randomisation of villages, from November 2018
to January 2019, we conducted a KAP survey in 50
randomly selected villages, on women who had delivered
a live baby within 2 years of the interview. We assessed
health service utilisation, beneficial and harmful
behaviours, and knowledge. This KAP survey will guide
the need and topics of further formative research for the
CHAMPION2 intervention.
Who will take informed consent? {26a}
All women and the main person responsible for children
who have been enumerated were informed about the
trial and gave their consent to participate. During the
trial, all women who are eligible to participate will be
informed and asked to give consent.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Participants may withdraw their consent at any time
during the trial. No biological specimen will be collected
during the trial. Women and caregivers will be free to
accept or not any interview during the trial.
Interventions
Explanation for the choice of comparators {6b}
The comparator for the maternal and neonatal health
package CHAMPION2 is the usual maternal and
neonatal health for the area, as that is the locally
accepted best practice. These villages will also receive
the educational intervention STRIPES2, as this allows
the evaluation of two independent interventions within
one trial. Analogously, the comparator for the education
package STRIPES2 is the usual education received in the
area, as that is the locally accepted best practice. These




Formative research (quantitative and/or qualitative) may
be carried out to help identify key areas (e.g. knowledge,
attitudes, behaviour, care, etc.) in need of improvement
through interviews and focus groups with local women,
healthcare providers and village elders. The intervention
in the CHAMPION2 trial will build on the knowledge
acquired in the original CHAMPION trial as well as
evidence published since the inception of the original
trial. The intervention will work with the existing
healthcare infrastructure and government services
including Anganwadis, NICE Nurse Midwives (NMW)
and ASHAs who will be tracking women and their
babies in the antenatal period, at birth, and in the
postnatal period. New services aimed at improving
1Children were included in cases where the day of birth was missing at
enumeration but the child was born between June 2010 and June 2013.
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health knowledge and increasing the uptake of services
will be created using ASHAs, Village Health Worker
(VHWs) (recruited as part of the intervention when
required as described below), and midwives. These
community health workers will endeavour to ensure
uniformity in quality of care across services in the
intervention arm.
A survey on the services and related infrastructure of
the health facilities was conducted according to the
Indian Public Health Standards (IPHS) [37]. Based on
this survey, NICE may facilitate modest improvements
to services provided at some CHCs. A small percentage
of high risk or emergency cases will be referred to
tertiary-level care.
The place of delivery will be discussed during birth
planning sessions and the intervention team will direct
pregnant women to plan for deliveries at designated
CHCs, CHs, or other hospitals. However, the final
choice of where they wish to deliver will be with the
family. Transportation to health facilities is currently
provided by the government (108 ambulance). If
government transport services are not available, the
intervention team may arrange alternative transport for
urgent cases. The intervention will include key elements
as subsequently described.
Health promotion
A health awareness campaign will be launched in the
different communities to promote knowledge relating to
maternal and neonatal health. Examples of the different
promotional strategies include focus groups and Nukkad
Natak’s (village-level street plays). These will be adapted
based on local customs to convey important messages to
communities. There will also be discussion groups
surrounding any concerns the communities have about
the intervention. All members of the community, and
not just women eligible for the trial, will be the focus of
these campaigns.
Community mobilisation with women’s groups
Community mobilisation with women’s groups used in
previous trials will be adapted to suit the context of the
local population [15]. All the women of the village, not
just the women eligible for the trial, will be allowed to
participate. The ASHA (VHW) with PLA teams will lead
the groups for sessions involving issues related to
maternal and neonatal health. Discussions about the risk
factors in pregnancy, the delivery, and the postnatal
period will be facilitated, and solutions will be derived to
tackle these issues. The objective of these meetings is to
improve mothers’ health knowledge, encourage greater
use of the fixed day service (see below), promote safe
delivery, encourage delivery of high-risk pregnancies at
an appropriate health centre, and to provide women a
forum to discuss solutions to important issues in mater-
nal and neonatal health.
Fixed day services (FDS) provided by ASHAs, VHWs, and
NICE nurse midwives
Teams of two midwives will visit the intervention
villages approximately every 2 weeks to offer a package
of antenatal and postnatal care and other services
relating to the mother and her baby. The midwives will
offer these services after the women’s group session,
assisted by an ASHA (VHW) based in the village. If a
woman is unable to attend the services, the midwives
and ASHA (VHW) will visit her at home. These services
will be given only to pregnant women identified by
NICE who have been enumerated and confirmed to be
eligible for the trial.
Examples of the different components of antenatal
care include the following: checking for anaemia
(haemoglobin levels), weight, monitoring for pre-
eclampsia (blood pressure, protein in urine), and moni-
toring for infections and gestational diabetes mellitus.
Examples of services provided in the delivery period in-
clude the following: promotion of a clean delivery and
other essential neonatal care practices, assisting a deliv-
ery where access to a health facility is not possible. Post-
natal services can include the following: advice on
breastfeeding (i.e. the importance of colostrum, initiating
breastfeeding within an hour of delivery, exclusive
breastfeeding for 6 months), care of the neonate (appro-
priate thermal care), and how to recognise danger signs
in mothers and babies.
To access these services, pregnant women will receive
the NICE ANC card for tracking immunisations,
participation in health groups, hospitalisations, and
regular check-ups (antenatal, postnatal, and neonatal).
The midwives will keep a record of visits to the village,
women seen, emergency deliveries assisted, and cases re-
ferred. The ASHAs (VHWs) and midwives will also keep
a detailed record of all their cases and meet regularly to
share information on their work and any problems
encountered.
Referrals
ASHAs (VHWs), and midwives will be responsible for
facilitating and monitoring the referrals of mothers and
neonates to the nearest CHC or CH that has adequate
human resources, equipment, medicines, and disposables
available.
ASHAs (community health workers)
At the community level, ASHAs will have a critical role in
delivering the intervention. A VHW may be appointed by
the trial when the ASHA is not consistently available, not
resident in the village, working in both intervention and
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control villages, not supporting the trial, or not
performing well. The trial team will recruit VHWs from
the local community based on their literacy,
communication proficiency, previous knowledge and
experience in pregnancy and childbirth (usually she will
be from the same village, educated until at least the 5th
grade, married, previously given birth, and recommended
by the community).
The ASHAs (VHWs) will receive a combination of
theoretical and practical training by midwives and
physicians, on the following topics: monitoring
pregnancies, identification of risk factors in both the
expectant woman and their baby, clean delivery
practices, appropriate thermal care, breast feeding,
appropriate care-seeking, arranging the logistics of refer-
rals in case of emergencies, building trust, and case
management.
NICE nurse midwife
A Nurse Midwife (NMW) employed by NICE will
provide the antenatal and postnatal care services after
the women’s group discussions. They will also offer
guidance to supervise ASHAs (VHWs). Midwives may
conduct emergency deliveries if they occur during their
visits to the villages and monitor referrals to health
facilities. In the case of complications, the NMW will be
responsible for referring the mother or neonate in
distress to the next level of care. Midwives will be
trained by physicians to deliver clear information related
to pregnancy, childbirth, and neonatal care, and the use
of communication tools to address deeply rooted
superstitions and practices that may have negative
impacts on the health of both mother and neonate.
STRIPES2
The education intervention comprises before/after school
teaching lessons for 2 h, typically 6 days a week given by a
“Pratham Instructor” (PI). Each PI will be trained and paid
to conduct teaching and learning activities in Hindi for a
group of up to about 30 eligible children in the village.
Thus, for the period of about 17months the same cohort of
children would receive the intervention. Pratham Cluster
Leaders (CLs) will support, coordinate, and monitor the
PI’s work.
The initial 2–3 weeks will be a warm-up phase. During
this period, the PIs will carry out a series of activities,
such as playing, singing, colouring, and drawing, to en-
able children to interact comfortably with the instruc-
tors. Thereafter, activities will be conducted to help PIs
understand what children can do easily and what they
are struggling with. After this period, the PI will begin
the instructional classes. The subject matter covered in
these sessions will reinforce the curriculum covered in
school and will develop children’s literacy and numeracy
skills in pace with their cognitive abilities.
Pratham has seen promising results when efforts are
made to engage with the primary caregivers (usually
mothers) of young children, to demonstrate and orient
them on activities that they can do with their children at
home [38]. PIs will thus have frequent contact with
mothers through door-to-door meetings, community
events, and creation of mothers’ groups. Mothers will be
oriented to engage in activities with their children to
promote their attendance and learning. The activities in
communities will thus build on Pratham’s past experi-
ence; not only building a strong foundation, but also try-
ing to create a sustainable learning environment that
supports children’s development.
Material kits
Pratham will develop material kits to be used during the
before/after school activities and at home. The material
for the classes will include the instructor’s manual and
teaching learning material such as story-books, activity
booklets, and more. In addition, Pratham teams will ori-
ent mothers on use of the home materials. Orientations
may be done in groups for easy comprehension of
mothers or one by one. Videos may also be shown for
this purpose.
Community consultants
Conflicts have arisen in previous community trials with
women who are dissatisfied with the services received
from the intervention team (e.g. unfavourable pregnancy
outcomes and expectation mismatch) or due to their
ineligibility for the antenatal care (ANC) and postnatal
care (PNC) services. One or more consultants with
expertise in handling such conflicts will facilitate
discussions to resolve these issues. A consultant will also
train and support ASHAs (VHWs) and supervisors in
interpersonal communication for effective interaction
with the communities.
Criteria for discontinuing or modifying allocated
interventions {11b}
Although the PLA may be slightly modified according to
local requests, there are no special criteria for
discontinuing or modifying allocated interventions.
Strategies to improve adherence to interventions {11c}
During the trial, the NICE and Pratham Foundations
will regularly visit the households of the participants to
promote awareness in a simplified manner. NICE nurses
and ASHAs (or VHWs) will sensitise mothers to: keep
track of their menstrual period, attend the PLA sessions
and FDS, and remind pregnant women about the
importance of their health assessments. Pratham
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instructors will regularly visit the households to engage
families to send their children to the Pratham classes
and explain to the caregivers how they can and should
talk with their children in a playful way about topics that
involve literacy and numeracy. Adherence will be
monitored by both groups, daily in Pratham classes
(pupils’ attendance) and every 2 weeks in the FDS (visits
by enumerated pregnant women) and monthly in the
PLA sessions (presence of enumerated women).
Relevant concomitant care permitted or prohibited
during the trial {11d}
The implementation of both Pratham classes and NICE
services will not affect the usual school hours or the
provision of antenatal and postnatal care that is
normally provided by the government, Anganwadis, and
ASHAs. Schools will function normally, and the health
services provided by the government will be offered
routinely to all women.
Provisions for post-trial care {30}
There are no special provisions for ancillary care. Although
there are no expectations of harm from trial participation,
in the event of harms, appropriate compensation will be
provided. The relevant interventions will be expanded to
the controls after the trial if proven to be successful.
Outcomes {12}
CHAMPION2
The primary outcome in CHAMPION2 is neonatal
mortality [39]. The secondary outcomes will include
maternal mortality [39]; stillbirths and perinatal
deaths [39]; causes of death [39]; antenatal care;
delivery care; immediate neonatal care; postnatal care;
health knowledge; hospital admissions of enrolled
women during pregnancy or afterwards, or of their
babies (during the neonatal period); maternal blood
transfusions; and the cost effectiveness of the
intervention.
STRIPES2
The primary outcome of STRIPES2 is the composite
literacy and numeracy test score using the Early
Grade Reading Assessment (EGRA) and the Early
Grade Mathematics Assessment (EGMA), respectively
[40–42].
Secondary outcomes include separate scores for
literacy and numeracy; parents’ engagement in their
child’s learning; enrolment in school; parent’s report of




Randomisation took place in June 2019. STRIPES2 will
run for about 17 months and CHAMPION2 will run for
3½ years.
A timeline with the key events during the trial is
presented in Table 1.
Sample size {14}
The process by which clusters (villages) were selected is
described subsequently (see “Recruitment”). After
application of the first three criteria to identify clusters
(steps 1–3), there are 484 villages that are potentially
eligible for the trial. Originally it had been the intention
to randomise 300 villages, because this gave over 90%
Table 1 Timeline of the key events in the trial
Date Event
December 2015 Protocol submitted to the L V PRASAD EYE
Institute (LVPEI) and London School of Hygiene
and Tropical Medicine (LSHTM) Ethics Committees
January to
October 2016
Permits sought and obtained from the
Departments of Health and Education in
Madhya Pradesh (Mission Director from the
National Health Mission, Director of the Child
Health for Madhya Pradesh, Additional Mission
and Director of the Education Department)
February 2017 Resubmission of protocol and short report to








Enumeration of the participants and data entry
September 2018 to
April 2019




Knowledge Attitudes and Practice (KAP) survey
interviews and data entry
April to June 2019 Catch-up enumeration
19 June 2019 Randomisation
June to
December 2019
Intervention design, village sensitisation and
trainings
October 2019 STRIPES2 intervention starts
December 2019 CHAMPION2 intervention starts
19 June 2020 Neonatal and maternal survival start to count to
final analysis
August 2020 First survey of children’s enrolment and attendance
in school
February 2021 Second survey of children’s enrolment and
attendance in school
March/April 2021 Final numeracy and literacy tests for children
(STRIPES2)
November 2021 Statistical analysis of STRIPES2 completed
December 2022 Final data collection for CHAMPION2
May 2023 Statistical analysis of CHAMPION2 completed
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statistical power to detect (1) a 20% reduction in
neonatal mortality in CHAMPION2 and (2) a difference
of 0.25 SD in mean standardised test scores in
STRIPES2. However, incorporating the buffer zones
described in the village selection procedure as described
previously meant that only 204 villages could be
selected. These 204 villages have a mean population of
1487 (minimum 558, maximum 2490) and SD of 505
(equating to a coefficient of variation of 0.34).
Estimating the number of children in each school year
from the number younger than 6 years (divided by 6),
the mean number of children in each school year is 38.3
(minimum 20, maximum 71) with SD of 13.3
(coefficient of variation 0.35). Assuming that 25% of the
children will not be eligible according to the criteria, this
gives an estimated mean number of eligible children per
village of 28.7 with a minimum of 15.
In CHAMPION the design effect for neonatal
mortality was 1.306, equating to an intra-cluster correl-
ation coefficient (ICC) of 0.011 (with allowance for vari-
ability in cluster size, the assumed coefficient of
variation = 0.34). For CHAMPION2, allowing for the fact
that each village has an average population of 1487 and
estimated crude birth rate of 30.7 per 1000 population
per year in rural areas of Satna district [3], 114 births
per village over a 30-month follow-up period are ex-
pected. Assuming (1) an ICC of 0.011 for the primary
outcome, (2) an assumed coefficient of variation for vil-
lage size variability of 0.34, (3) that 5% of villages will be
excluded for reasons such as withholding consent, and
(4) that there will be 10% loss to follow up, a trial with
194 villages (95% of 204) has 75% power (5% two-sided
significance) to detect a 20% reduction in neonatal mor-
tality from 6.7% to 5.36% and 91% power (5% 2-sided
significance) to detect a 25% reduction in neonatal mor-
tality from 6.7% to 5.0% (this and other power and sam-
ple size calculations were performed using the “power”
command in Stata 14) [43]. Since the reduction in neo-
natal mortality seen in CHAMPION was 25%, proceed-
ing with 204 villages seems reasonable given the
requirement for buffer zones in order to avoid
contamination.
We estimated that the 204 villages will include an
average of 28.7 eligible students (5740 students in total).
In the STRIPES trial the estimated effect was a 0.75 SD
increase in mean score: however, effects of smaller
magnitude than this would still be important to detect.
Conservatively assuming that 60% of the eligible
children (4860 students) will take the test at the end of
the trial and an ICC of 0.23 (as seen in the STRIPES
trial) then a trial with 194 villages (i.e. assuming that 5%
of the 204 villages will not take part) will give 88%
power to detect a difference of 0.25 SD in mean
standardised scores between intervention and control
villages using a conventional two-sided significance level
of 5% (assuming a coefficient of variation of 0.35 in
numbers taking the test by village). If the treatment ef-
fect is of the order of that seen in the STRIPES trial then
there will be reasonable statistical power to explore in-
teractions by ethnicity, gender, wealth, and geographic
location.
As described above, in the sample size calculation we
anticipated that 194 of the 204 villages would be
randomised. In fact, 196 were randomised, with 6
villages removed since they were found to be too close
to urban areas to be considered rural, and 2 removed
because insufficient eligible children were found.
Recruitment {15}
Following discussion with the Sarpanch (the head of a
Panchayat, which is a group of villages), all eligible
children and women were enumerated in all villages in
which we obtained village consent. These villages were
selected from all villages in Satna district that satisfy the
eligibility criteria.
Cluster identification
The pathway to select villages (clusters) was the following:
1. We selected Satna district from the census 2011 data;
2. The tehsils of Birsinghpur, Majhgawan and
Raghurajnagar were excluded (difficult access, risk
of violent robbery, and urban sub-district);
3. Villages with a population larger than 2500 and
fewer than 120 children under the age of 6 years
(suggesting fewer than 20 children in each school
year) were excluded;
4. Villages within 5 km of a CHC or CH were
excluded;
5. Using a programme developed in the statistical
package Stata, villages were selected using an
algorithm that attempts to maximise both (i) the
total number of villages selected and (ii) the
population of selected villages, whilst ensuring that
there is a distance of at least 3 km between the
centre of each pair of selected villages (buffer zones
to reduce contamination);
6. During the enumeration period, we will identify the
eligible children, women and men in each selected
village;
7. If a selected village cannot be included (if, for
example, consent is refused or there are insufficient
eligible children) then this village should be
dropped from the selected list and can be replaced
by one or more substitute villages not originally
selected, provided that there is a distance of at least
3 km between each pair of selected villages.
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Randomisation
Randomisation was at the village (cluster) level, with
stratification by village size and distance to the nearest
CHC or CH.
Control groups
CHAMPION2 control villages will receive the STRIPES2
intervention and the usual health services provided by
the government, private, and other Non-Governmental
Organisations (NGOs). STRIPES2 control villages will
receive the CHAMPION2 intervention and the usual
education services provided by the government and
other NGOs.
It is anticipated that the CHAMPION2 intervention
will have negligible impact on children’s learning scores,
and the STRIPES2 intervention will have negligible
impact on neonatal mortality. The fact that these
interventions are being carried out may improve the
extent and quality of the data collected in the control
villages. The relevant interventions will be expanded
into the controls if proven to be successful.
Randomisation flowchart
The process from village selection to inclusion in the
final analysis is shown in Fig. 1.
Assignment of interventions
Sequence generation {16a}
The trial statistician based at the London School of
Hygiene and Tropical Medicine randomised the clusters
using a random number generator. Randomisation was
stratified by population size and distance to the nearest
CHC or CH.
Concealment mechanism {16b}
All villages were simultaneously randomised on 19 June
2019 using a random number generator. Following
randomisation (which was post enumeration and cluster
consent), the trial statistician informed the intervention
providers (NICE and Pratham) about which villages had
been allocated to each intervention. Since there was no
sequential allocation there was no need for a
concealment mechanism after the initial randomisation.
Fig. 1 Flowchart of villages through trial. CHC, Community Health Centre
Agarwal et al. Trials          (2020) 21:569 Page 11 of 18
The intervention providers then informed the villages.
Allocation was concealed up to that point.
Implementation {16c}
Independent teams hired and trained by GH Training and
Consulting registered the participants. The trial
statistician at the London School of Hygiene and Tropical
Medicine performed randomisation, and then shared the
allocation information with the intervention providers.
Once the lists of villages allocated to receive the health
and education packages were shared with NICE and
Pratham respectively, each intervention provider started
the process of community sensitisation.
Assignment of interventions: blinding
Who will be blinded {17a}
Due to the nature of the interventions, it will not be
possible to have a blinded study. Participants will be
aware as to whether they are in the CHAMPION2 or
STRIPES2 intervention arm. Nevertheless, all physicians
who will be assigning a cause of death using the World
Health Organisation’s verbal autopsy toolkit [44] in
CHAMPION2, and the teams who will be carrying out
testing in STRIPES2 (hired and trained by GH Training
and Consulting)2 will be blind to the randomisation.
Procedure for unblinding if needed {17b}
The trial is not blinded, so there is no need for unblinding.
Data collection and management
Plans for assessment and collection of outcomes {18a}
An independent research team based in Satna will
manage the enumeration, monitoring, surveys and tests.
Except for the list of eligible participants in the trial, no
further data will be shared by the research team during
the trial. A set of procedures will be established to
recruit, train and monitor the research staff, preserving
the segregation from the intervention group.
It will be possible to locate enumerated participants
including women, unmarried men, children, and parents,
by assigning an ID number that is a combination of the
village identifier, and household identifier.
For CHAMPION2, women were interviewed during
enumeration about their previous obstetric and
pregnancy-related history. Neonatal deaths were assessed
for the year before enumeration through recall based on a
truncated pregnancy history. Once the intervention starts,
participating women will be continuously monitored. Un-
married men will also be enumerated and monitored to
determine if they marry. If an unmarried man marries, his
wife becomes a resident of the village, and if she gives
consent to participate in the trial, then she will be followed
up in cycles of 30–33 days.
Research teams will visit all the trial villages in a cycle
of 30–33 days to register new pregnancies, follow up
those already recorded, interview for pregnancy
outcomes and follow up the neonatal status until the
baby is age 29 days. Research teams will also monitor
enumerated unmarried men to determine if they have
recently been married. If a woman is recorded to be
pregnant and leaves the village, the research team
should attempt to ascertain her pregnancy outcome
from her as part of the cycle of household visits, or by
calling her over the phone or interviewing her family (if
she does not come back to the village).
Deaths (neonates up to and including the 28th day of
life or women who died pregnant or within 42 days after
the delivery) will be investigated to ascertain the possible
cause of death using verbal autopsies developed by the
WHO and adapted for local understanding. Stillbirths will
be defined as the death of a foetus from the 28th week of
gestation and before birth [45]. To ascertain the weeks of
gestation we will use the last menstrual period (LMP)
recorded when research teams first become aware that a
woman is pregnant. Two physicians, blinded to allocation,
will independently assign the cause of death. In the case of
disagreement on one main cause of death, a third
physician will be recruited to resolve the disagreement.
In STRIPES2, a follow-up survey will be conducted
twice during the trial to update the status (residence,
school enrolment, and attendance) of those children en-
listed. In one of these surveys, we will also record infor-
mation to generate a wealth index.
Literacy and numeracy tests will be administered by
the end of the intervention to all children enumerated
who are available in the village on the test day. Both the
tests will be designed to measure a student’s foundation
skills in literacy and numeracy in the early grades.
Plans to promote participant retention and complete
follow up {18b}
There will be no rewards or incentive for participants,
except that children will be offered a small gift when
taking the final test (such as a snack or piece of
stationery, which will be decided upon close to the date
of the test). All the outcome data that has been collected
up to the last monitoring for CHAMPION2 and in the
final test for STRIPES2 will be included in the analysis
unless consent has been withdrawn.
Data management {19}
All data related to pregnancies, births, deaths, children’s
school enrolment, parent’s engagement in the child’s
education and the final EGRA and EGMA (literacy and
numeracy) tests will be double-entered in the main
2The final literacy and numeracy tests will be administered by a person
blind to which villages are holding the Pratham classes.
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office of the research team in Satna. The database has
been developed by Sealed Envelope (https://www.seale-
denvelope.com), an independent company contracted to
construct and maintain a bespoke database for the trial,
who will also keep a periodical backup of the data. Paper
forms will be stored there in a secure location and
destroyed after the statutory period expires.
Confidentiality {27}
All data will be kept strictly confidential - names will be
removed from the database before analysis and the
paper data collection instruments will be kept in a
secure location in Satna, Madhya Pradesh, and destroyed
after the statutory period expires.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Prior to commencing statistical analysis, a detailed
statistical analysis plan will be written by the trial
statistician. This will be considered by the trial Steering
and Data Monitoring Committees and signed off by the
Principal Investigator before statistical analysis is carried
out.
CHAMPION2
The primary analysis of all outcomes will follow the
intention-to-treat principle, with a secondary per-
protocol analysis of the primary outcome also under-
taken. As this trial has a complex hierarchical structure,
with multiple women per cluster, potentially multiple
pregnancies per women, and potentially multiple births
per pregnancy, we will use a generalised estimating
equations (GEE) analysis approach [46]. This assumes
non-independence of all observations from the same
cluster, and accounts for non-independence of multiple
outcomes from the same woman.
For the primary outcome, the relative risk with a 95%
confidence interval will be obtained from a GEE model
with a binary outcome, a log link, a “working”
assumption of independence with robust standard errors
to take account of clustering. The model will include the
stratifying variables [47, 48]. The risk difference with a
95% confidence interval will be obtained from a GEE
model with a binary outcome, an identity link, a
“working” assumption of independence with robust
standard errors to take account of clustering. This
model will also include the stratifying variables. The
numbers of lives saved will be estimated by multiplying
the number of live births in the intervention arm by the
estimated risk difference. Relative risks will be estimated
for secondary binary outcomes, using the same approach
as for the primary outcome.
STRIPES2
The primary analysis of all outcomes will also follow the
intention-to-treat principle, with a secondary per-
protocol analysis of the primary outcome also under-
taken. Mean child-specific composite test scores at the
end of the final academic year will be compared using
regression models with adjustment for stratification fac-
tors and with robust standard errors to allow for cluster-
ing by village. Bootstrap confidence intervals will be
reported for non-normally distributed continuous out-
comes. Intervention–gender interactions will be tested.
A secondary per-protocol analysis of the respective
primary outcomes will be carried out in both CHAM-
PION2 and STRIPES2. This will exclude participants in
the respective intervention arms deemed not to have sat-
isfied adherence criteria that will be pre-specified in the
statistical analysis plan.
Economics
We will measure the cost effectiveness from the
provider point of view. Project cost will be collected
prospectively and converted to economic cost. Cost data
will be adjusted for inflation, using the Indian consumer
price index and reported in Indian Rupees and US
dollars in the equivalent period. Incremental cost
effectiveness will be measured relative to the status quo
alternative as defined by outcomes in the control arms.
Interim analyses {21b}
CHAMPION2 interim analyses will be pre-specified and
provided confidentially by the trial statisticians to an in-
dependent Data Monitoring Committee (DMC), which
will be guided by the Peto-Haybittle rule [49] with a rec-
ommendation to stop made on the basis of a large and
statistically significant (p < 0.001) difference in either dir-
ection. The DMC will report to the Trial Steering Com-
mittee (TSC). As in STRIPES2 there are no concerns
about the safety of the intervention, and as there is
only one assessment of the primary efficacy outcome,
there will be no such interim analysis for STRIPES2.
Methods for additional analysis {20b}
Secondary analyses in both CHAMPION2 and STRIPES2
will extend the models described above for the respective
primary outcomes to (separately) investigate interactions by
the two stratification factors (village size and distance to the
nearest Community Health Centre or Civil Hospital).
Methods in analysis to handle protocol non-adherence
and missing data {20c}
Per-protocol analysis will be carried out in both
CHAMPION2 and STRIPES2. This will exclude
participants in the respective intervention arms deemed
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not to have satisfied adherence criteria that will be pre-
specified in the statistical analysis plan. In the event of
substantial missing data, secondary analysis using tech-
niques such as multiple imputation will be considered,
with details pre-specified in a supplementary statistical
analysis plan.
Plans to give access to the full protocol, participant level-
data, and statistical code {31c}
The protocol will be publicly available from this website.
The datasets analysed during the current study are
available from the corresponding author on reasonable
request.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
Trial management group
The trial will have independent implementation and
research teams. A TSC, with independent membership
(an obstetrician, a paediatrician, and an education
researcher) will supervise the trial.
Implementation team
The team in charge of implementing and managing the
CHAMPION2 intervention will be composed of:
1. The Programme Officer (PO) who will oversee the
implementation of the whole programme assisted
by junior programme officers (JPOs);
2. ASHAs (VHWs) who will be responsible for the
following: mobilising the community for FDS,
facilitating the community mobilisation with
women’s groups, monitoring pregnant women,
imparting health education, helping to conduct
home deliveries in emergency situations, and
facilitating referrals;
3. Nurse midwives who will: provide services in the
FDS, supervise the ASHAs (VHWs), help
deliver babies if needed, and give logistical support
in the villages;
4. Field Monitors who will supervise ASHAs (VHWs),
facilitate FDS, and monitor referrals to health
facilities;
5. Consultants in maternal and neonatal health,
community mobilisation and support, and liaison
who will monitor patient care logistics and
outcomes, build team capacity in community
sensitisation, and support in resolving community-
level issues;
6. A team lead by JPO will be conducting and
managing the Participatory Learning and Action
(PLA).
The STRIPES2 intervention team will consist of:
1. National and state team members who will provide
ongoing guidance and support to the programme;
2. A Programme Head (PH) who will liaise with the
local government officers and with internal state
and central teams. She/he will oversee the teams’
operations on the ground and be responsible for
implementation of the education intervention;
3. Two Content Associates who will provide content
support to the teams. They will work with members
from Pratham’s central content team to design/
develop teaching and learning materials for the
intervention;
4. A Monitoring, Measurement and Evaluation
Associate who will be responsible for training teams
on and analysing internal measurements;
5. Cluster leaders (CLs) - each CL will be responsible
for about 10 villages. They will provide training and
supervision to the Pratham instructors, whilst also
facilitating engagement with the community;
6. Pratham instructors (PIs) who will lead the classes,
monitor every child’s learning progress, and liaise
with mothers.
The research team responsible for enumerating all the
participants, monitoring pregnant women and neonates,
conducting the tests, and collecting the data that will be
used to evaluate the impact of the interventions is
composed of:
1. One Project Coordinator who will be responsible
for leading the research teams (health and
education), organising training, and liaising with
other Coordinators and the Database team;
2. Survey Enumerators who will visit households and
conduct interviews during enumeration and for the
annual survey (STRIPES2);
3. Village Enumerators (VEs) who will be monitoring
whether the enumerated women are alive, pregnant,
and present in the village during the 30–33-day
cycle (CHAMPION2);
4. Data Supervisors (DSs) who will lead the field
research teams and supervise and facilitate the work
of all enumerators. They will verify the completed
forms and conduct quality checks to validate them;
monitor neonates; and complete pregnancy
outcome questionnaires, verbal autopsies and
interviews to enrol women married into the trial
villages;
5. A Training Coordinator who will organise
induction and team monthly meetings, and liaise
with the Database Manager and field teams for
data-related issues;
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6. Data Supervisors for Verbal Autopsies (DSVA) who
are responsible for conducting the verbal autopsy
interviews (MVA and NVA);
7. Cluster Coordinators (CC) who will coordinate the
work of the data supervisors; lead meetings;
organise the distribution of forms; and engage in
community interaction along with supervisors;
8. A Field Manager who will be in charge of the
monitoring-cycle data (CHAMPION2). She/he will
select the field staff, organise the forms distribution,
and verify the quality and validate the data
collected;
9. A Database Manager who will be responsible for
coordinating the data entry operators; correcting
double entry inconsistencies; coordinating the
printing and distribution of forms; liaising with the
database programmer in London; and manage the
database and assure its integrity;
10. Data Entry Operators who will double-enter all the
data;
11. Physicians who will attribute the cause of death at
maternal and neonatal verbal autopsies;
12. Test Administrators who will conduct the final tests
for STRIPES’ evaluation.
Composition of the Data Monitoring Committee (DMC),
its role and reporting structure {21a}
The CHAMPION2 DMC includes a statistician and a
clinician, both independent of the trial and the Sponsor.
The primary role of the DMC is to safeguard the
interests of the study participants and to enhance the
integrity and credibility of the trial. The DMC will
report to the TSC.
Adverse event reporting and harms {22}
Information will be collected about harms - serious
adverse events (SAEs). An SAE is formally defined as
any untoward occurrence that results in death; is life-
threatening; requires inpatient hospitalisation or pro-
longation of existing hospitalisation; results in persistent
or significant disability/incapacity; or is a congenital
anomaly/birth defect [50].
For this trial, SAEs are defined as deaths (stillbirths,
neonatal, and maternal), maternal blood transfusions,
hospital admissions other than for labour, and prolongation
of existing hospitalisation (beyond 48 h). Information about
persistent or significant disability/incapacity or congenital
anomaly/birth defect will not be collected due to the
difficulty of ascertaining this in routine data collection in
this trial but if a child dies, information about birth defects
will be collected within the verbal autopsy process.
Information about SAEs will be collected as part of routine
outcome data collection in the villages by the research
team.
In addition, if any other serious but unexpected
adverse event is seen which might be related to a trial
intervention, this should be logged by calling the trial
coordinator (TC) and a written SAE report submitted.
The TC will coordinate the reporting of all such events
within 7 days to the L V PRASAD EYE Institute and
London School of Hygiene and Tropical Medicine Ethics
Committees. This expedited reporting will be limited to
those outcomes not already listed as primary or
secondary outcomes, yet which might reasonably occur
as a consequence of the trial intervention.
Frequency and plans for auditing trial conduct {23}
The TMG will meet (remotely) approximately once a
month. The TSC and the independent DMC and Ethics
Committee will meet approximately annually.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
The TMG will notify relevant partners of changes to the
protocol and update the clinical trial registry. The DMC
will be informed about any major deviations from
protocol. We will provide updates of the protocol in the
clinical trial registry and inform the Ethics Committees
of major changes.
Dissemination plans {31a}
We will attempt to disseminate the results of the trial in
international, national, state and district conferences,
and to villages participating in the trial, and publish the
findings in peer-reviewed journals following the Consoli-
dated Standards for Reporting Trials (CONSORT) guid-
ance for cRCTs [51]. All publications must be approved
by the Trial Steering Committee.
Trial status
MP trial protocol Version 11th Version - 20 March
2020.
Recruitment of participants started on 1 June 2017
and will continue till approximately December 2021 for
eligible women (CHAMPION2). For STRIPES2, no more
children will be added to the list of participants.
Randomisation was in June 2019. The trial
interventions are scheduled to start from October–
December 2019.
Definitions
Early neonatal deaths: deaths of neonates within 7 days
of delivery (i.e. 0–7 days) [39].
Emergency Obstetric Care (EmOC): a package of
medical interventions required to treat seven obstetric
complications [34]. The medical interventions include
parenteral antibiotics, oxytocic drugs and anticonvulsants,
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manual removal of placenta, removal of retained products,
and assisted vaginal deliveries [35].
Late neonatal deaths: neonatal deaths occurring
between the 8th and 29th day of life [39].
Maternal death: defined by the World Health
Organisation as death of a women whilst pregnant or
within 42 days of termination of pregnancy, irrespective of
the duration and site of pregnancy, from any cause related
to or aggravated by the pregnancy or its management but
not from accidental or incidental causes [39].
Maternal mortality ratio: the ratio of maternal deaths
per 100,000 live births [52].
Neonatal mortality rate: the number of deaths of a
new born infant during the first 28 completed days of
life per 1000 live births [39].
Perinatal deaths: refers to pregnancy loss at or beyond
28 weeks gestation and early neonatal dates within 7
days of delivery [39].
Perinatal mortality rate: the number of perinatal
deaths per 1000 total births in a given year. The
perinatal period starts at the beginning of foetal viability
(28 weeks of gestation) and ends at the end of the 7th
completed day after delivery. Perinatal deaths are the
sum of stillbirths plus early neonatal deaths [41].
Sarpanch: an elected head of a village-level statutory
institution of local self-government called the Panchayat
(village government) in India, Pakistan, and Bangladesh.
The Sarpanch is the focal point of contact between gov-
ernment officers and the village community.
Stillbirth: refers to pregnancy loss at or beyond 28
weeks gestation without any signs of life [41].
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Consent for publication {32}
Participants (household heads, women, and caregivers on behalf of children)
were informed that we would revisit the households to interview them
about pregnancies, babies, and children’s school enrolment so we could
understand to the impact of the CHAMPION2 and STRIPES2 programmes. All
participants agreed that all individual information collected during interviews
will be used only for research purposes and in ways that will not reveal their
identity.
Ethics approval and consent to participate {24}
The Ethics Committees of L V PRASAD Eye Institute, Hyderabad, India (LEC
02–16-008) and London School of Hygiene and Tropical Medicine (LSHTM
Ethics Ref: 10482) have approved the trial protocol. We have obtained the
necessary approvals from the Indian Council of Medical Research, New Delhi
and the Government of Madhya Pradesh to conduct this trial in Satna
district. The trial complies with the Declaration of Helsinki, local laws, and the
International Conference on Harmonisation Good Clinical Practice (ICH-GCP).
Any protocol modifications will be communicated to both the Ethics
Committees, and consent will be re-obtained at the village and individual
(woman or parents) level at that point if deemed necessary.
For this trial, we received approval from the Indian Medical Council of
Research (ICMR), New Delhi, India. At the state level, approval of the protocol
was obtained from the Department of Health & Family Welfare of the
government of Madhya Pradesh.
This trial employs multiple tiers of consent: village, individual, and individual
on behalf of the child. Agreement to approach eligible villages was first
obtained from the Sarpanch. In the trial villages, consent was obtained from
the village after the trial has been presented in a meeting with village elders
representing all the castes and village residents. Verbal consent was given
during a village meeting with written documentation (or thumbprint) of the
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approval given by the Sarpanch. This process of obtaining consent through
meetings with approval of the “guardians” of the clusters is common in trials
in which the intervention is delivered at the level of a cluster and it is not
possible to obtain informed consent for randomisation from individuals
within the cluster before a baseline survey.
Once the trial was accepted at the village meeting, the villages were
considered eligible for baseline enumeration. During the process of baseline
interview, each head of household, each potentially eligible woman and one
parent or care-giver of each potentially eligible child was informed in the
local language (Hindi) about the trial and their participation and asked for a
signature or thumbprint to indicate their consent to join the trial. Only
people who agreed to participate were enumerated. Women and parents of
enumerated children have the right to withdraw consent at any time during
the trial. This process of consent is compatible with current standards for
cluster randomised trials [53].
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